GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (CHIX:PCIBo) » Definitions » Book Value per Share

PCI Biotech Holding ASA (CHIX:PCIBO) Book Value per Share : kr1.26 (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is PCI Biotech Holding ASA Book Value per Share?

PCI Biotech Holding ASA's book value per share for the quarter that ended in Jun. 2023 was kr1.26.

During the past 12 months, PCI Biotech Holding ASA's average Book Value Per Share Growth Rate was -32.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -40.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -36.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PCI Biotech Holding ASA was 103.20% per year. The lowest was -53.90% per year. And the median was -25.80% per year.

PCI Biotech Holding ASA's current price is kr1.92. Its book value per share for the quarter that ended in Jun. 2023 was kr1.26. Hence, today's PB Ratio of PCI Biotech Holding ASA is 1.84.

During the past 13 years, the highest P/B Ratio of PCI Biotech Holding ASA was 10.60. The lowest was 0.20. And the median was 2.26.


PCI Biotech Holding ASA Book Value per Share Historical Data

The historical data trend for PCI Biotech Holding ASA's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Book Value per Share Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.84 5.07 3.05 1.54 1.05

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.54 1.40 1.26 1.05

Competitive Comparison of PCI Biotech Holding ASA's Book Value per Share

For the Biotechnology subindustry, PCI Biotech Holding ASA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's PB Ratio distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's PB Ratio falls into.



PCI Biotech Holding ASA Book Value per Share Calculation

PCI Biotech Holding ASA's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(39.04-0.00)/37.33
=1.05

PCI Biotech Holding ASA's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(46.91-0.00)/37.33
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


PCI Biotech Holding ASA  (CHIX:PCIBo) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


PCI Biotech Holding ASA Book Value per Share Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (CHIX:PCIBO) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (CHIX:PCIBO) Headlines

No Headlines